Advertisement

Topics

Biologics, Inc. Company Profile

16:43 EDT 22nd September 2017 | BioPortfolio

BioLogics manufactures the OMNICON Antibiotic Zone Reader, Tumor Colony Analyzer, Ultrasonic Homogenizer (Sonicator, Cell Disrupter, Sonifier, Sonic Dismembrator, Cell Disruptor) and Automated Colony Counter

Location

9024 Euclid Avenue
Suite H
Manassas
Virginia
20110
United States of America

Contact

Phone: 703-367-9020
Fax: 703-367-9024
Email: mzervoudis@biologics-inc.com


News Articles [571 Associated News Articles listed on BioPortfolio]

Publication of the Securities Note Having Obtained Visa No. 17-297 of the AMF in Connection with the Capital Increase of GenSight Biologics

NOT FOR DISTRIBUTION IN THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA AND JAPAN. Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), ("GenSight Biologics...

Heat Biologics, Inc.: Dr. Jeff Hutchins Appointed Chief Operating Officer for Heat Biologics

DURHAM, NC / ACCESSWIRE / July 3, 2017 / Heat Biologics, Inc. ("Heat") (Nasdaq: HTBX), a leader in the development of novel therapies designed to activate a patient's immune system against cancer, ...

Samsung Bioepis Forms Novel Biologics JV with Takeda Pharma

Samsung Bioepis, a division of Samsung Biologics, announced a joint venture with Japan's Takeda Pharma to develop novel biologic drugs. The JV's first project will be TAK-671, a candidate aimed at sev...

Heat Biologics, Inc.: Heat Biologics to Present Poster at 2017 ASCO Annual Meeting

DURHAM, NC / ACCESSWIRE / May 30, 2017 / Heat Biologics, Inc. ("Heat") (NASDAQ: HTBX), a leader in the development of novel therapies designed to activate a patient's immune system against cancer, ...

Heat Biologics, Inc.: Heat Biologics Appoints Damien Hallet as Vice President of CMC Development

DURHAM, NC / ACCESSWIRE / July 3, 2017 / Heat Biologics, Inc. ("Heat") (Nasdaq: HTBX), a leader in the development of novel therapies designed to activate a patient's immune system against cancer, ...

Samsung Bioepis and Takeda enter biologics co-development deal

Samsung Bioepis Co. Ltd., a joint venture formed by Samsung BioLogics and Biogen Inc., and Takeda Pharmaceutical Co. Ltd. entered an agreement to co-fund and co-develop biologics for diseases of unmet...

CMC Biologics, Trellis BioScience in Development and Mfg. Pact

CMC Biologics will use CHEF1 Expression Platform and Multi-column Continuous Chromatography Technology

Sanofi continues biologics push, building on recent approvals

The French drugmaker expects to invest €600 million a year in biologics production over the next several years. 

Drugs and Medications [3 Associated Drugs and Medications listed on BioPortfolio]

Standardized cat pelt [Jubilant HollisterStier LLC]

ALLERGENIC EXTRACT STANDARDIZED CAT PELT AP ACETONE PRECIPITATED

Standardized cat hair [Jubilant HollisterStier LLC]

ALLERGENIC EXTRACT STANDARDIZED CAT HAIR AP Acetone Precipitated

Cinryze [ViroPharma Biologics]

These highlights do not include all the information needed to use CINRYZE™ safely and effectively. See full prescribing information for CINRYZE.CINRYZE™ (C1 Esterase Inhibitor [Human]) For Intrave...

PubMed Articles [109 Associated PubMed Articles listed on BioPortfolio]

Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis.

Biologic disease-modifying anti-rheumatic drugs (DMARDs: referred to as biologics) are effective in treating rheumatoid arthritis (RA), however there are few head-to-head comparison studies. Our syste...

Prolongation of biologic dosing intervals in patients with stable psoriasis: a feasibility study.

Biologics are usually licensed according to the "one dose fits all" principle. It is therefore suspected that a significant number of psoriasis patients are overtreated. However, evidence for successf...

Biosimilars: biologics that meet patients' needs and healthcare economics.

Biologics have revolutionized medical care, yet uniform access to these effective medicines remains difficult due to the increasing costs of healthcare. As patent exclusivity on the early biologics wa...

The expanding field of biologics in the management of chronic urticaria.

Chronic urticaria (CU) is the occurrence of urticaria with or without angioedema for at least 6 weeks. Management has traditionally involved antihistamines as first-line therapy with various alternati...

Treatment of rheumatoid arthritis with biologics may exacerbate HTLV-1-associated conditions: A case report.

There are roughly 5 to 10 million persons infected with human T-lymphotropic virus type 1 (HTLV-1) worldwide, and the safety of treating this population with biologics remains poorly understood.

Clinical Trials [60 Associated Clinical Trials listed on BioPortfolio]

Ustekinumab Safety and Surveillance Program Using the Ingenix NHI Database

The patients included in this observational study will be drawn from a research database containing claims and enrollment data for members of a large, geographically diverse US health plan...

Golimumab Safety and Surveillance Program Using the Ingenix NHI Database

The participants included in this observational study will be drawn from a research database containing claims and enrollment data for members of a large, geographically diverse US health ...

Real World Effectiveness of Ustekinumab in Induction and Maintenance Therapy for Crohn´s Disease

"RUN-CD" is an investigator initiated "Non interventional Trial" on biologics in Crohn´s Disease (CD) patients in Germany with a prospective documentation of effectiveness in induction an...

Tight Control Dose Reductions of Biologics in Psoriasis Patients With Low Disease Activity

Rationale/hypothesis: Moderate-to-severe psoriasis can be treated with biologics. Objective To investigate whether the dose of biologics can be reduced in patients with psoriasis with sta...

Observational Study to Estimate the Effectiveness of Biologics When Treating Plaque Psoriasis

To estimate the real-world effectiveness of approved biologics in subjects with moderate-to-severe plaque psoriasis who are either starting or switching biologic medication.

Companies [234 Associated Companies listed on BioPortfolio]

Burst Biologics

Burst Biologics is a rapidly growing Biotechnology Company and federally registered tissue bank located in Boise, Idaho. Burst Biologics is a developer of effective tissue process...

MSD Biologics (UK) Limited

Avecia Biologics was acquired in February 2010 by MSD, the UK subsidiary of Merck & Co Inc, the world’s second largest pharmaceutical company. MSD Billingham is one of the world's leading contract ...

Precision Biologics, Inc.

Founded in February 2012 and commencing business in late September 2012, Precision Biologics, Inc. is a clinical stage biotechnology corporation focused on developing therapeutic ...

GT Biologics

GT Biologics is focused on the research and development of Live Biotherapeutics (LBPs) for the treatment of autoimmune diseases. GT Biologics aim to deliver a new class of medicine based on the po...

Permeon Biologics

Permeon Biologics is pioneering a breakthrough class of intracellular biologics that target a broad spectrum of previously undruggable targets. Leveraging its novel Intraphilinâ...

More Information about "Biologics, Inc." on BioPortfolio

We have published hundreds of Biologics, Inc. news stories on BioPortfolio along with dozens of Biologics, Inc. Clinical Trials and PubMed Articles about Biologics, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Biologics, Inc. Companies in our database. You can also find out about relevant Biologics, Inc. Drugs and Medications on this site too.

Quick Search
Advertisement
 

Corporate Database Quicklinks



Searches Linking to this Company Record